Result for
Topic: Vaccines and Immunity
February 25, 2021
Suspected Recurrent SARS-CoV-2 Infections Among Residents of a Skilled Nursing Facility During a Second COVID-19 Outbreak — Kentucky, July–November 2020
SARS-CoV-2 reinfection is suspected among residents of a skilled nursing facility in Kentucky, where 5 residents received positive RT-PCR test results in two separate COVID-19 outbreaks separated by 3 months with at least four negative test results for each resident in between the outbreaks. While only 2 of 5 patients had symptomatic infection during the…
February 24, 2021
Healthcare Personnel Knowledge Motivations Concerns and Intentions Regarding COVID-19 Vaccines a Cross-Sectional Survey
[Pre-print, not peer-reviewed] A cross-sectional survey of healthcare professionals (HCP) (n=2,448) from three Northern California medical centers conducted from November 16-December 8, 2020 indicated that overall enthusiasm for the COVID-19 vaccine was strong, and more HCP (69%) said they would definitely/likely receive vaccine if it were formally FDA-approved versus if it were approved via emergency…
SARS-CoV-2 B.1.1.7 Sensitivity to MRNA Vaccine-Elicited, Convalescent and Monoclonal Antibodies
[Pre-print, not peer-reviewed] An assessment of immune responses following a single dose of the Pfizer-BioNTech vaccine (BNT162b2) vaccine using pseudoviruses expressing the wild-type Spike protein or the B.1.1.7 spike protein showed that the vaccine-elicited antibodies modestly reduced activity against the B.1.1.7 variant. This reduction was also observed in sera from some convalescent patients and with…
Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting
The Johnson & Johnson single-dose Ad26.COV2.S vaccine candidate was determined by the FDA to have met the safety and efficacy requirements for emergency use authorization. Vaccine efficacy against laboratory-confirmed moderate to severe/critical COVID-19 across all geographic areas in which the trial was conducted was 66.9% when considering cases occurring at least 14 days after the…
February 23, 2021
Single-Dose Administration and the Influence of the Timing of the Booster Dose on Immunogenicity and Efficacy of ChAdOx1 NCoV-19 (AZD1222) Vaccine: A Pooled Analysis of Four Randomised Trials
Pooled analysis of four randomized placebo-controlled trials (total n=24,422) of the Oxford-AstraZeneca ChAdOx1 nCov-19 (AZD1222) vaccine show that overall efficacy against symptomatic SARS-CoV-2 infection >14 days after the second dose was 66.7% (95%CI: 57.4-74.0%), with 84 cases (1% cumulative incidence) in the 8,597 participants in the vaccine group and 248 cases (2.9% cumulative incidence) in…
Effectiveness of First Dose of COVID-19 Vaccines against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People
[Pre-print, not peer-reviewed] A national prospective cohort study including approximately 99% of residents in Scotland (n=5.4 million) found a peak vaccine efficacy to prevent COVID-19-related hospitalization following a first dose of 85% (95% CI: 76-91%) for the Pfizer vaccine and 94% (95%CI: 73-99%) for the Oxford-AstraZeneca vaccine, with the peak occurring at 28-34 days post-vaccination….
Demographic Benchmarks for Equitable Coverage of the COVID-19 Vaccination Program among Priority Populations
[Pre-print, not peer-reviewed] Essential healthcare workers included in the Phase 1a population defined by the Advisory Committee on Immunization Practices (ACIP) prioritized for vaccination were estimated to have a larger share of women (74%), non-Hispanic Black individuals (18%), and adults aged 25-44 years (41%) compared to the general US population. Phase 1b has a more…
Reduced Binding and Neutralization of Infection- and Vaccine-Induced Antibodies to the B.1.351 (South African) SARS-CoV-2 Variant
[Pre-print, not peer-reviewed] Antibodies collected from people who had been infected with SARS-CoV-2 or who had received the Moderna vaccine showed lower levels of binding to the SARS-CoV-2 B.1.351 variant (first described in South Africa) compared to the D614G variant that has been dominant globally. This effect was observed for antibodies from individuals with acute…
February 22, 2021
Use of Convalescent Plasma in Patients with Coronavirus Disease (Covid-19) Systematic Review and Meta-Analysis
[Pre-print, not peer-reviewed] A systematic review and meta-analysis of convalescent plasma (CP) treatment indicated that CP had no effect on mortality (RR = 1.02), and that evidence was insufficient to recommend the use of CP in the treatment of moderate or severe COVID-19. The analysis identified 10 randomized controlled trials involving 11,854 patients in which…
The Rise of SARS-CoV-2 Variant B.1.1.7 in Israel Intensifies the Role of Surveillance and Vaccination in Elderly
[Pre-print, not peer-reviewed] An analysis of over 300,000 RT-PCR samples collected in Israel between December 6th, 2020 and February 10th, 2021 in the general community and nursing homes found that the B.1.1.7 variant outcompeted the wildtype SARS-CoV-2 strain, representing 90% of positive tests. The variant was 45% more transmissible than wildtype. In addition, the transmission…
Previous page Next page